Table 2.

Effect of i.c.v. infusion of the MCH1 receptor antagonist on food intake, tissue weights and plasma blood parameters (Experiment 2)

	Sham	OVX
		Vehicle	Antagonist
Cumulative food intake (g)	103.1±3.7	118.5±4.3#	103.3±2.2**
Tissue weights
Mesenteric fat weight (g)	0.34±0.04	0.57±0.05##	0.24±0.03**
Liver weight (g)	1.44±0.02	1.77±0.10#	1.50±0.03*
Liver TG (mg g liver−1)	12.0±1.0	15.1±1.1	10.3±0.8**
Blood parameters
Glucose (mM)	9.0±0.2	10.1±0.4	9.9±0.5
Insulin (ng ml−1)	0.9±0.2	1.4±0.1#	1.0±0.1**
Leptin (ng ml−1)	7.4±1.0	16.7±2.0##	5.6±0.7**
Total CHL (mM)	1.4±0.1	1.7±0.0##	1.6±0.0**
TG (mg l−1)	487±44	486±41	411±42
FFA (μeq l−1)	394±20	444±26	380±23

Abbreviations: CHL, cholesterol; FFA, free fatty acid; i.c.v., intracerebroventricular; TG, triglyceride.

Starting 6 months after OVX, the MCH1 receptor antagonist was administered for the next 4 weeks. Data shown are means±s.e.

^#P<0.05, 0.01 vs sham-operated group.

^##P<0.05, 0.01 vs sham-operated group.

^*P<0.05, 0.01 vs vehicle-treated OVX group.

^**P<0.05, 0.01 vs vehicle-treated OVX group.